首页> 外文期刊>Medicine. >Clinical significance of costimulatory molecules CD40/CD40L and CD134/CD134L in coronary heart disease: A case-control study
【24h】

Clinical significance of costimulatory molecules CD40/CD40L and CD134/CD134L in coronary heart disease: A case-control study

机译:共刺激分子CD40 / CD40L和CD134 / CD134L在冠心病中的临床意义:病例对照研究

获取原文
           

摘要

The aim of the study was to evaluate the potential role of CD40/CD40 ligand (CD40L) and CD134/CD134 ligand (CD134L) in the development of coronary heart disease (CHD) via the performance of a case-control study. The research objects were 234 cases of CHD patients and 120 cases of well-matched normal controls. Following the separation of peripheral blood mononuclear cells (PBMCs), real-time quantitative PCR (qRT-PCR), Western blot, immunohistochemistry, and flow cytometry were applied for the detection of mRNA levels and expression levels of CD40/CD40L and CD134/CD134L; meanwhile, intercellular adhesion molecule-1 (ICAM-1) and Fas protein mRNA levels were detected using qRT-PCR. There was no statistical difference in the comparison of baseline characteristics between groups, indicating comparability between groups. qRT-PCR and Western blot analysis indicated that CD40/CD40L and CD134/CD134L mRNA and protein expression levels were all increased in the CHD group than those in the control group. Flow cytometry further confirmed the similar tendency. Meanwhile, ICAM-1 and Fas protein mRNA levels were elevated in the CHD group and positively correlated with the above parameters. Furthermore, CD40/CD40L expression rates were negatively correlated with gender and different types of CHD. Meanwhile, CD134/CD134L expressions were also higher in male patients, in patients with family history, previous history of hypertension, diabetes, and cerebrovascular diseases. CD40/CD40L and CD134/CD134L are increased and may have potential correlation with clinical pathological features of patients with CHD. Further in-depth exploration of costimulatory molecules for CHD guidance as well as intrinsic mechanisms are needed combined with in vivo and in vitro experiments.
机译:该研究的目的是通过病例对照研究评估CD40 / CD40配体(CD40L)和CD134 / CD134配体(CD134L)在冠心病(CHD)发生中的潜在作用。研究对象为234例CHD患者和120例完全匹配的正常对照。分离外周血单个核细胞(PBMC)后,应用实时定量PCR(qRT-PCR),蛋白质印迹,免疫组织化学和流式细胞仪检测CD40 / CD40L和CD134 / CD134L的mRNA水平和表达水平。 ;同时,采用qRT-PCR检测细胞间粘附分子-1(ICAM-1)和Fas蛋白mRNA水平。各组之间基线特征的比较无统计学差异,表明各组之间具有可比性。 qRT-PCR和蛋白质印迹分析表明,CHD组的CD40 / CD40L和CD134 / CD134L的mRNA和蛋白质表达水平均高于对照组。流式细胞仪进一步证实了类似的趋势。同时,冠心病组ICAM-1和Fas蛋白mRNA水平升高,与上述参数呈正相关。此外,CD40 / CD40L表达率与性别和不同类型的冠心病呈负相关。同时,CD134 / CD134L表达在男性患者,有家族史,既往有高血压,糖尿病和脑血管疾病的患者中也较高。 CD40 / CD40L和CD134 / CD134L升高,可能与冠心病患者的临床病理特征具有潜在的相关性。结合体内和体外实验,需要进一步深入探索用于CHD指导的共刺激分子及其内在机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号